Directorio independiente

Hospital Civil de Guadalajara Fray Antonio Alcalde

Guadalajara. Esta página agrupa registros donde ClinicalTrials.gov publica nombres de sede que coinciden con este centro dentro de las condiciones que monitoreamos.

Perfil informativo no verificado por el centro

Construido a partir de registros públicos; no implica afiliación.

Sin afiliación: BiomedicalResearch.mx no afirma representar a este centro y no garantiza que este listado sea completo. Confirma siempre nombre, dirección, contacto y estatus en el registro oficial.

Variantes de nombre encontradas

  • Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde"
  • Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde
  • Hospital Civil Fray Antonio Alcalde
  • Hospital Civil de Guadalajara Fray Antonio Alcalde

Estudios detectados

ReclutandoNCT07405801

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Fase 2Hoffmann-La Roche
Ver registro oficial ↗
ReclutandoNCT05646862

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Fase 3Hoffmann-La Roche
Ver ficha informativa
ReclutandoNCT05894239

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Fase 3Hoffmann-La Roche
Ver registro oficial ↗
ReclutandoNCT06790693

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Fase 3Hoffmann-La Roche
Ver registro oficial ↗
ReclutandoNCT07368998

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

Fase 2Hoffmann-La Roche
Ver registro oficial ↗
ReclutandoNCT06875310

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Fase 3Mirati Therapeutics Inc.
Ver ficha informativa
ReclutandoNCT07144280

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Fase 3Pfizer
Ver registro oficial ↗
ReclutandoNCT06793215

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Fase 3Hoffmann-La Roche
Ver registro oficial ↗
ReclutandoNCT05920356

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Fase 3Amgen
Ver registro oficial ↗
ReclutandoNCT06112314

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Fase 3Immunocore Ltd
Ver ficha informativa